Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

280.01 -13.99 (-4.76%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
47 48 Next >
The Short List Of Dow Jones Stocks That Are Actually Up This Year: Hint — It's Very Short
The stock market has had a rough going for the first nine months of the year in 2022. All the major indexes are down year-to-date, including the Dow Jones Industrial Average. Here’s a look at the four... 
Via Benzinga
Warning! A Housing Market Crash Will Tank These 3 Stocks.
Don't be complacent about a potential black-swan event. A housing market crash would send these three stocks plunging. 
Via InvestorPlace
The 7 Best Stocks to Buy to Tap Into a Hidden Bull Market
Despite the ongoing worries on Wall Street, these are the best stocks to buy to play the hidden bull market. 
Via InvestorPlace
Amgen Whale Trades Spotted
A whale with a lot of money to spend has taken a noticeably bearish stance on Amgen. Looking at options history for Amgen (NASDAQ:AMGN) we detected 22 strange trades. 
Via Benzinga
Amgen's Lumakras Cuts Risk Of Progression By 34% In KRAS-Mutated Lung Cancer Patients
Via Benzinga
AskSlim Market Week - Friday, Sept. 9
Technical and cycle analysis, and market commentary. 
Via Talk Markets
Costco Down After Earnings as Analysts Fret About Company Facing Higher Costs
(Friday Market Open) The end of the week isn’t bringing much relief for investors. 
Via Benzinga
Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test
Though successful in early testing, it wasn't enough to win a Phase 3 study. 
Via Investor's Business Daily
$100 Invested In This Stock 15 Years Ago Would Be Worth $400 Today
Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 3.43% on an annualized basis producing an average annual return of 9.79%. Currently, Amgen has a market capitalization of... 
Via Benzinga
Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year
The biotech run off a June bottom is great — until you realize you could've netted more. 
Via Investor's Business Daily
Take-Two Gets Beat Down After Leak of Its Popular Grand Theft Auto VI
(Monday Market Open) Equity index futures are pointing to a lower open as the Federal Open Market Committee meets tomorrow and announces their interest rate decision on Wednesday. 
Via Benzinga
Amgen's Repatha Shows Long Term Lowering Of Bad Cholesterol, Tolerance
Via Benzinga
Top US Drugmakers Exploit US Patent System To Keep Generic Competition At Bay: Report
Via Benzinga
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
US Department Of Health, Defense To Inject $1B To Boost Domestic Biomanufacturing
Via Benzinga
Biden Administration Pushes 'Cancer Moonshot' Initiative: Report
President Joe Biden channeled John F. Kennedy on the 60th anniversary of the former President's moonshot speech, highlighting the Biden administration's efforts to "end cancer as we know it."  The... 
Via Benzinga
Livent, Amgen And Some Other Big Stocks Moving Lower On Monday
U.S. stocks traded higher, with the Dow Jones gaining more than 250 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Bristol-Myers Squibb (BMY) Stock Jumps 8% as FDA Approves Psoriasis Treatment
Bristol-Myers Squibb is going after Amgen's $2 billion a year Otezla franchise with Sotyktu. BMY stock is up on the news. 
Via InvestorPlace
Here's Why Amgen Shares Are Diving
Amgen, Inc. (NASDAQ: AMGN) shares are trading lower by 4.11% to $237.51 during Monday's pre-market session following FDA approval of Bristol Myers Squibb Co's (NYSE: BMY) plaque psoriasis drug Sotyktu,... 
Via Benzinga
Top Financial Stories Monday, September 12: Netflix Collaborates With Assassin's Creed Maker, Gun Sales Could Soon Be Tracked Via Payment Processors, Xi Jinping To Meet Vladimir Putin In First Foreign Trip And More...
Bloomberg Tesla, Nio Supplier CATL's Chinese Rival Eyes $2B Hong Kong IPO 
Via Benzinga
Bristol Myers' Deucravacitinib Scores FDA Approval For Plaque Psoriasis
Via Benzinga
7 Dow Stocks With Superior Fundamentals
Robust Dow stocks offer attractive deals for patient investors amidst an unstable economic environment 
Via InvestorPlace
3 Dividend Stocks: A Smarter Way To Boost Your Retirement Income
Here are three dividend-paying stocks retirees should consider for their nest egg portfolio. 
Via Talk Markets
These 3 S&P 500 Dividend Stocks Have High Compound Annual Growth Rates Through 2024
Based on consensus estimates among surveyed analysts, FactSet has determined which stocks in the S&P 500 that have the highest expected two-year dividend compound annual growth rate. 
Via Benzinga
Here's How Much You Would Have Made Owning Amgen Stock In The Last 20 Years
Amgen (NASDAQ:AMGN) has outperformed the market over the past 20 years by 1.16% on an annualized basis producing an average annual return of 8.7%. Currently, Amgen has a market capitalization of... 
Via Benzinga
Stocks Extend Losing Streaks Amid Steep Monthly Declines
Stocks closed out August with another selloff, with all three major indexes logging a fourth-straight daily loss and finishing August in the red. 
Via Talk Markets
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar. 
Via Benzinga
Why Amgen's Cancer Drug Results Gave This Small Cap A Big Boost
Amgen says Lumakras beat out chemo in patients with non small-cell lung cancer. 
Via Investor's Business Daily
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Amgen Shares Climb As Late-Stage Lung Cancer Study Meets Primary Endpoint
Amgen (NASDAQ: AMGN) has announced top-line results from the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS (sotorasib) in patients with KRAS G12C-mutated non-small cell lung... 
Via Benzinga
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
47 48 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.